Altimmune, Inc.

Good day, ladies and gentlemen, and welcome to Altimmune, Inc. First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Rich Eisenstadt, Chief Financial Officer of Altamune. Rich, you may begin.

Thank you, Gigi, and good morning, everyone. Thank you for participating in Altamune's first quarter 2024 Financial Results and Business Update Conference Calls. Members of Altamine's team joining me on the call today are Vipin Garg, our chief executive officer, Scott Harris, our chief scientific officer, or Scott Roberts, our chief scientific officer, and Scott Harris, our chief medical officer. Following the prepared remarks from Vipin, Scott, Harris, and myself, we will hold a question and answer session. A press release with our first quarter 2024 financial results was issued this morning. and can be found on the investor relations section of the company's website. Before we begin, I'd like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Aldermen cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For discussion of some of the risks and factors that could affect the company's future results and operations, please see the risk factors and other cautionary statements contained in the company's filings with the SEC. I will also direct you to read the forward-looking statement disclaimer in our press release issued this morning and now available on our website. Any statements made on this conference call speak only as of today's date, Thursday, May 9th, 2024, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio replay on Altamune's website. With that, I will now turn the call over to Dr. Vipin Garg, Chief Executive Officer of Altamune. Vipin?

Thanks, Rich. Good morning, everyone. And once again, thank you for joining us for our first quarter corporate update. On our last call, I shared our excitement about our accomplishments in 2023 with respect to the advancement of Pembidutide in the obesity and MASH indications that we are currently pursuing. We remain optimistic about the potential of our differentiated GLP-1 glucagon dual receptor agonist to contribute to the treatment of these two important diseases as we continue working towards our next milestones in each of these programs. Looking first at obesity. The body composition data from the Phase II Momentum Trial we reported at the end of March demonstrated that 74.5% of weight loss came from body fat and only 25.5% of weight loss came from lean mass in patients taking pembidutide. This is comparable to effects associated with diet and exercise based on historical data. This degree of lean mass preservation together with the significant overall weight loss and robust reductions in liver fat and serum lipids observed in each of our prior clinical trials could position pembidutide as a best-in-class therapy for individuals with obesity and dyslipidemia or excess liver fat. These impressive results will be part of a comprehensive package of clinical and preclinical data that we plan to present to the FDA at our end of phase two meeting, which we expect will be held late in the third quarter of 2024. We look forward to this meeting, which will help guide the design and conduct of our Phase III Registrational Program for pembidutide in obesity. Turning to MASH, we are continuing to enroll patients in the IMPACT Study, a Phase IIb biopsy-driven trial, evaluating two dosages of pembidutide against placebo in approximately 190 subjects. Top line results expected in the first quarter of 2025. Pembidutide is poised to be the first incretin-based therapeutic candidate to read out on a biopsy-based endpoint in MASH after just 24 weeks of treatment. A reflection of our confidence in the ability of pembidutide to treat the liver inflammation and fibrosis that characterizes MASH. We believe that these data, if positive, could give Pembidutide a meaningful advantage over other entrant-based candidates being studied in MASH and further strengthen our competitive position as we enter late-stage development. As you are all aware, our long-term goal remains to partner Pembidutide, and we are firmly committed to finding a partner with the ability to maximize the near and long-term value of the program for Altimmune and our shareholders, and who recognizes the significant potential of our candidate in obesity and MASH, as well as other potential indications. In parallel with these ongoing partnering efforts and the continued advancement of Pembidutide for MASH, we are taking additional steps to further leverage the pipeline in a drug potential of pembidutide. We are not yet in a position to share specific details around additional indications or development plans beyond the two currently being studied, but we believe this is a valuable initiative. These efforts are underway, and I look forward to providing additional information as our plans take shape. With that, I'll now turn the call over to our Chief Medical Officer, Dr. Scott Harris to discuss our plans. Scott?